Skip to content

Effect of mind therapy and exercise therapy in patients with pain

Combined Effect of Hypnotic-Cognitive Therapy with Therapeutic Exercise on Quality of Life in Individuals with Fibromyalgia: A Randomized Controlled Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/07/091248
Enrollment
104
Registered
2025-07-21
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M00-M99- Diseases of the musculoskeletal system and connective tissue

Interventions

Intervention1: Hypnotic cognitive therapy and therapeutic exercise: The study protocol will be given for 12 weeks in total. Hypnotic cognitive therapy will be given 8 individual sessions in span of 12

Sponsors

Manipal Academy of Higher Education
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Fibromyalgia diagnosed by 2016 AMerican College of Rheumatology Fibromyalgia diagnostic criteria by Rheumatologists for more than 1 year 2. Fibromyalgia Impact Questionnaire Revised score more than 30 3. Ability to read, speak, and understand English or Hindi or Kannada language

Exclusion criteria

Exclusion criteria: 1.Patients participated in a designed exercise training program in the past 6 months 2.Patients undergoing any other psychological and complementary & alternate therapies such as mindfulness, chiropractic, massage in the past 6 months 3.Patients with psychological and neurological disorders such as dementia, Alzheimer s disease, parkinsonism, major depressive and personality disorders 4.Patients with known serious cardiovascular disease such as uncontrolled arterial hypertension, uncontrolled DM, Metabolic diseases 5.Pregnant women 6.Individuals presented with chronic inflammatory rheumatic diseases such as rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematous

Design outcomes

Primary

MeasureTime frame
Fibromyalgia Impact Questionnaire RevisedTimepoint: At baseline (0 weeks), End of the treatment (12 weeks)

Secondary

MeasureTime frame
Patient-Reported Outcomes Measurement Information System Sleep disturbance scale-short formTimepoint: At baseline (0 weeks), End of the treatment (12 weeks);Patient-Reported Outcomes Measurement Information System Fatigue-short formTimepoint: At baseline (0 weeks), End of the treatment (12 weeks);Pain Pressure ThresholdTimepoint: At baseline (0 weeks), End of the treatment (12 weeks);Muscle EnduranceTimepoint: At baseline (0 weeks), End of the treatment (12 weeks)

Countries

India

Contacts

Public ContactDr Prem V

Manipal College of Health Professions, Manipal Academy of Higher Education

prem.v@manipal.edu9886647732

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026